Pulse oximetry has measured oxygen and pulse rate reliably for decades, but it has never been expected to flag atrial fibrillation or opioid-induced respiratory depression in real time. Masimo’s FDA 510(k) clearance for smartSET changes that expectation, at least on paper. The AFib detection component posted 97% sensitivity and 100% specificity in clinical validation, measured against three clinicians reading concurrent ECG strips as the ground truth standard, which is a meaningful bar for a photoplethysmography-based tool.
The clinical logic is straightforward. AFib affects more than 10% of patients over 65 and frequently goes undetected until a stroke event. On the OIRD side, one in 10 surgical patients receiving opioids experiences an opioid-related adverse event, and 85% of postoperative OIRD events occur within the first 24 hours after surgery. Both conditions share a common failure mode in hospital settings: they develop silently between nursing rounds, in patients already attached to a device that, until now, only reported SpO2 and pulse rate. SmartSET layers AI-driven pattern recognition across SpO2, pulse rate, and perfusion index to generate escalating notifications on the Radius VSM wearable, rather than waiting for a clinician to notice a trend in raw numbers.
There are important limits to note. The PPG-based AFib capability signals that a rhythm is suggestive of AFib; it does not replace ECG confirmation and is cleared to supplement the decision for AFib screening in patients 18 and older. The device is a prompt for further evaluation, not a diagnosis. For trial teams running postoperative studies, where OIRD is a documented safety concern and continuous monitoring compliance is a recurring protocol challenge, a cleared continuous-monitoring tool that automates pattern detection on a wearable is operationally relevant, particularly in general care floor settings where telemetry is not standard.
Masimo SET is already the primary pulse oximetry platform at all 10 top U.S. hospitals in the 2026 Newsweek World’s Best Hospitals ranking and is estimated to monitor more than 200 million patients annually. That installed base gives smartSET immediate distribution reach, which means the validation numbers will face real-world scrutiny quickly. How the AFib flagging rate holds up across heterogeneous inpatient populations, including patients with other arrhythmias, is the figure worth watching as post-market data accumulates.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
